E3A06: Phase II/III Study of Lenalidomide vs Observation in Asymptomatic, High-Risk Smoldering Multiple Myeloma

Source: 2019 American Society of Clinical Oncology Annual Meeting*
Download Slideset
May 31 - June 4, 2019; Chicago, Illinois
Lenalidomide significantly decreased the risk of progression vs observation in patients with high-risk smoldering multiple myeloma.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 5, 2019

Acknowledgements

Provided by the USF Health
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Amgen
Celgene Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings